Why the study?
Beyond natriuretic peptides and troponins, the utility of novel, emerging biomarkers in heart failure management is less established.
This consensus document provides expert guidance on the use of established and emerging biomarkers in the management of heart failure.
Provides ESC consensus on HF biomarker monitoring; leaves open validation and integration of novel markers.
The role of biomarkers is increasingly recognized in heart failure (HF) management, for diagnosis, prognostication, and screening of high-risk patients. Beyond natriuretic peptides and troponins, the utility of novel, emerging biomarkers is less established. This document reflects the key points of a Heart Failure Association of the European Society of Cardiology (ESC) consensus meeting on biomarker monitoring in HF.
No takes yet. Share an insight, caveat, or question.
Spoletini et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: